TGTX earnings: next report 2026-08-03, real EPS beat/miss history, analyst consensus Buy, P/E 16.57. Updated 2026-07-23.
TG Therapeutics (TGTX) Research Hub
TG Therapeutics (TGTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 53.89 USD (-1.39%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 16.57, market cap 8.12B. This hub links to the full technical, earnings and options research available for TGTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 53.89 USD (-1.39%) |
| 52-week range | 45.37 USD – 59.3 USD |
| Trend regime | Range |
| 14-day RSI | 62.4 (Bullish) |
| Trailing P/E | 16.57 |
| Market cap | 8.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for TGTX
Covered Call on TGTX: how it works, illustrative setup around the real 53.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TGTX: how it works, illustrative setup around the real 53.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TGTX: how it works, illustrative setup around the real 53.89 USD price, max profit/loss, breakeven and when to use it. Educational.
TGTX technical analysis: range, last 53.89 USD, RSI 62.4, 52w range 45.37 USD–59.3 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TGTX in?
TG Therapeutics (TGTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TGTX in an uptrend or downtrend?
As of 2026-09-11, TGTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TGTX's trailing P/E ratio?
TGTX's trailing P/E is 16.57, with a market cap of 8.12B. See the earnings research page for full valuation detail.
When does TGTX next report earnings?
TGTX is next scheduled to report earnings on 2026-08-03, with a consensus EPS estimate of 0.3171 USD.